Copyright Reports & Markets. All rights reserved.

Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 5 mg/mL
    • 1.3.3 10 mg/mL
    • 1.3.4 25 mg/mL
    • 1.3.5 50 mg/mL
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospitals
    • 1.4.3 Clinic
    • 1.4.4 Others
  • 1.5 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size & Forecast
    • 1.5.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity (2021-2032)
    • 1.5.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Roche Holding AG
    • 2.1.1 Roche Holding AG Details
    • 2.1.2 Roche Holding AG Major Business
    • 2.1.3 Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
    • 2.1.4 Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Roche Holding AG Recent Developments/Updates
  • 2.2 Bristol Myers Squibb Co.
    • 2.2.1 Bristol Myers Squibb Co. Details
    • 2.2.2 Bristol Myers Squibb Co. Major Business
    • 2.2.3 Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
    • 2.2.4 Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Bristol Myers Squibb Co. Recent Developments/Updates
  • 2.3 Elea Spa
    • 2.3.1 Elea Spa Details
    • 2.3.2 Elea Spa Major Business
    • 2.3.3 Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
    • 2.3.4 Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Elea Spa Recent Developments/Updates
  • 2.4 Eli Lilly & Co.
    • 2.4.1 Eli Lilly & Co. Details
    • 2.4.2 Eli Lilly & Co. Major Business
    • 2.4.3 Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
    • 2.4.4 Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Eli Lilly & Co. Recent Developments/Updates
  • 2.5 Merck & Co., Inc.
    • 2.5.1 Merck & Co., Inc. Details
    • 2.5.2 Merck & Co., Inc. Major Business
    • 2.5.3 Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
    • 2.5.4 Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Merck & Co., Inc. Recent Developments/Updates
  • 2.6 AstraZeneca PLC
    • 2.6.1 AstraZeneca PLC Details
    • 2.6.2 AstraZeneca PLC Major Business
    • 2.6.3 AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
    • 2.6.4 AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 AstraZeneca PLC Recent Developments/Updates
  • 2.7 Regeneron Pharmaceuticals, Inc.
    • 2.7.1 Regeneron Pharmaceuticals, Inc. Details
    • 2.7.2 Regeneron Pharmaceuticals, Inc. Major Business
    • 2.7.3 Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
    • 2.7.4 Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Regeneron Pharmaceuticals, Inc. Recent Developments/Updates
  • 2.8 Henlius Biopharma Co., Ltd
    • 2.8.1 Henlius Biopharma Co., Ltd Details
    • 2.8.2 Henlius Biopharma Co., Ltd Major Business
    • 2.8.3 Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
    • 2.8.4 Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Henlius Biopharma Co., Ltd Recent Developments/Updates
  • 2.9 Jiangsu Hengrui Medicine Co., Ltd
    • 2.9.1 Jiangsu Hengrui Medicine Co., Ltd Details
    • 2.9.2 Jiangsu Hengrui Medicine Co., Ltd Major Business
    • 2.9.3 Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
    • 2.9.4 Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Jiangsu Hengrui Medicine Co., Ltd Recent Developments/Updates
  • 2.10 Innovent Biologics Co., Ltd
    • 2.10.1 Innovent Biologics Co., Ltd Details
    • 2.10.2 Innovent Biologics Co., Ltd Major Business
    • 2.10.3 Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
    • 2.10.4 Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Innovent Biologics Co., Ltd Recent Developments/Updates
  • 2.11 Junshi Biosciences Co., Ltd
    • 2.11.1 Junshi Biosciences Co., Ltd Details
    • 2.11.2 Junshi Biosciences Co., Ltd Major Business
    • 2.11.3 Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
    • 2.11.4 Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Junshi Biosciences Co., Ltd Recent Developments/Updates
  • 2.12 BeiGene, Ltd
    • 2.12.1 BeiGene, Ltd Details
    • 2.12.2 BeiGene, Ltd Major Business
    • 2.12.3 BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
    • 2.12.4 BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 BeiGene, Ltd Recent Developments/Updates
  • 2.13 Akeso, Inc
    • 2.13.1 Akeso, Inc Details
    • 2.13.2 Akeso, Inc Major Business
    • 2.13.3 Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Product and Services
    • 2.13.4 Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Akeso, Inc Recent Developments/Updates

3 Competitive Environment: Monoclonal Antibodies for Non-small Cell Lung Cancer by Manufacturer

  • 3.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Manufacturer (2021-2026)
  • 3.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Monoclonal Antibodies for Non-small Cell Lung Cancer by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturer Market Share in 2025
  • 3.5 Monoclonal Antibodies for Non-small Cell Lung Cancer Market: Overall Company Footprint Analysis
    • 3.5.1 Monoclonal Antibodies for Non-small Cell Lung Cancer Market: Region Footprint
    • 3.5.2 Monoclonal Antibodies for Non-small Cell Lung Cancer Market: Company Product Type Footprint
    • 3.5.3 Monoclonal Antibodies for Non-small Cell Lung Cancer Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Region
    • 4.1.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Region (2021-2032)
    • 4.1.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Average Price by Region (2021-2032)
  • 4.2 North America Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2021-2032)
  • 4.3 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2021-2032)
  • 4.5 South America Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Type (2021-2032)
  • 5.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Type (2021-2032)
  • 5.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Application (2021-2032)
  • 6.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Application (2021-2032)
  • 6.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Type (2021-2032)
  • 7.2 North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Application (2021-2032)
  • 7.3 North America Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Country
    • 7.3.1 North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Type (2021-2032)
  • 8.2 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Application (2021-2032)
  • 8.3 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Country
    • 8.3.1 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Region
    • 9.3.1 Asia-Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Type (2021-2032)
  • 10.2 South America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Application (2021-2032)
  • 10.3 South America Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Country
    • 10.3.1 South America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Country
    • 11.3.1 Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Monoclonal Antibodies for Non-small Cell Lung Cancer Market Drivers
  • 12.2 Monoclonal Antibodies for Non-small Cell Lung Cancer Market Restraints
  • 12.3 Monoclonal Antibodies for Non-small Cell Lung Cancer Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Monoclonal Antibodies for Non-small Cell Lung Cancer and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Monoclonal Antibodies for Non-small Cell Lung Cancer
  • 13.3 Monoclonal Antibodies for Non-small Cell Lung Cancer Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Monoclonal Antibodies for Non-small Cell Lung Cancer Typical Distributors
  • 14.3 Monoclonal Antibodies for Non-small Cell Lung Cancer Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Monoclonal Antibodies for Non-small Cell Lung Cancer market size was valued at US$ 14710 million in 2025 and is forecast to a readjusted size of US$ 30190 million by 2032 with a CAGR of 10.9% during review period.
    Non-Monoclonal Antibodies for Non-small Cell Lung Cancer are a class of biological agents targeting specific targets of non-small cell lung cancer (NSCLC), aiming to enhance the body's immune response by targeting specific antigens or immune checkpoints on the surface of cancer cells, thereby inhibiting tumor growth and metastasis. These monoclonal antibodies can be used to treat advanced or recurrent NSCLC, often in combination with chemotherapy or other immunotherapies, to increase treatment efficacy and improve patient survival.
    This report is a detailed and comprehensive analysis for global Monoclonal Antibodies for Non-small Cell Lung Cancer market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Monoclonal Antibodies for Non-small Cell Lung Cancer market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Monoclonal Antibodies for Non-small Cell Lung Cancer market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Monoclonal Antibodies for Non-small Cell Lung Cancer market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Monoclonal Antibodies for Non-small Cell Lung Cancer market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Monoclonal Antibodies for Non-small Cell Lung Cancer
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Monoclonal Antibodies for Non-small Cell Lung Cancer market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche Holding AG, Bristol Myers Squibb Co., Elea Spa, Eli Lilly & Co., Merck & Co., Inc., AstraZeneca PLC, Regeneron Pharmaceuticals, Inc., Henlius Biopharma Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd, Innovent Biologics Co., Ltd, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Monoclonal Antibodies for Non-small Cell Lung Cancer market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    5 mg/mL
    10 mg/mL
    25 mg/mL
    50 mg/mL
    Market segment by Application
    Hospitals
    Clinic
    Others
    Major players covered
    Roche Holding AG
    Bristol Myers Squibb Co.
    Elea Spa
    Eli Lilly & Co.
    Merck & Co., Inc.
    AstraZeneca PLC
    Regeneron Pharmaceuticals, Inc.
    Henlius Biopharma Co., Ltd
    Jiangsu Hengrui Medicine Co., Ltd
    Innovent Biologics Co., Ltd
    Junshi Biosciences Co., Ltd
    BeiGene, Ltd
    Akeso, Inc
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Monoclonal Antibodies for Non-small Cell Lung Cancer product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Monoclonal Antibodies for Non-small Cell Lung Cancer, with price, sales quantity, revenue, and global market share of Monoclonal Antibodies for Non-small Cell Lung Cancer from 2021 to 2026.
    Chapter 3, the Monoclonal Antibodies for Non-small Cell Lung Cancer competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Monoclonal Antibodies for Non-small Cell Lung Cancer breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Monoclonal Antibodies for Non-small Cell Lung Cancer market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Monoclonal Antibodies for Non-small Cell Lung Cancer.
    Chapter 14 and 15, to describe Monoclonal Antibodies for Non-small Cell Lung Cancer sales channel, distributors, customers, research findings and conclusion.

    Buy now